Literature DB >> 8730346

Economic and social impact of migraine.

C E Clarke1, L MacMillan, S Sondhi, N E Wells.   

Abstract

We sent an anonymous self-administered questionnaire to 4200 employees of a Trust hospital, 1903 of whom returned it. We identified 158 migraine sufferers according to International Headache Society (IHS) criteria. These sufferers estimated 2.0 days/year absence from work, and an equivalent of 5.5 days/year lost by reduced effectiveness at work, caused by their migraine at an estimated financial cost of over 50,000 pounds to the Trust. An additional 220 individuals who had received a diagnosis of migraine from a doctor but fulfilled only 3/4 IHS criteria lost the equivalent of 6.7 days off work at a further cost of 63,000 pounds). Few patients had consulted their general practitioner about their migraines in the last 3 months. Most (78%) were using only over-the-counter medication. Migraine patients should be encouraged to seek medical attention.

Entities:  

Mesh:

Year:  1996        PMID: 8730346     DOI: 10.1093/oxfordjournals.qjmed.a030141

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  39 in total

Review 1.  Ibuprofen with or without an antiemetic for acute migraine headaches in adults.

Authors:  Roy Rabbie; Sheena Derry; R Andrew Moore; Henry J McQuay
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Sumatriptan plus naproxen for acute migraine headaches in adults.

Authors:  Simon Law; Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2010

3.  Zolmitriptan for acute migraine headaches in adults.

Authors:  Sheena Derry; R Andrew Moore; Henry J McQuay
Journal:  Cochrane Database Syst Rev       Date:  2010

4.  Headache disorders: differentiating and managing the common subtypes.

Authors:  Fayyaz Ahmed
Journal:  Br J Pain       Date:  2012-08

5.  Eletriptan for acute migraine headaches in adults.

Authors:  Sheena Derry; R Andrew Moore; Henry J McQuay
Journal:  Cochrane Database Syst Rev       Date:  2010

Review 6.  Sumatriptan. A pharmacoeconomic review of its use in migraine.

Authors:  A J Coukell; H M Lamb
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

7.  A multinational investigation of the impact of subcutaneous sumatriptan. I: Design, methods and clinical findings.

Authors:  J Heywood; J Bouchard; P Cortelli; C Dahlöf; J P Jansen; S Pham; J Hirsch; C E Edwards; J Adams; P Berto; B Brueggenjuergen; A L Nyth; P Lindsay; K L Price
Journal:  Pharmacoeconomics       Date:  1997       Impact factor: 4.981

8.  Relationship between air mass type and emergency department visits for migraine headache across the Triangle region of North Carolina.

Authors:  Christopher Elcik; Christopher M Fuhrmann; Andrew E Mercer; Robert E Davis
Journal:  Int J Biometeorol       Date:  2017-09-13       Impact factor: 3.787

9.  Usefulness of the SF-8 Health Survey for comparing the impact of migraine and other conditions.

Authors:  Diane M Turner-Bowker; Martha S Bayliss; John E Ware; Mark Kosinski
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

10.  Employment outcomes of persons with a mental disorder and comorbid chronic pain.

Authors:  Jennifer Brennan Braden; Lily Zhang; Frederick J Zimmerman; Mark D Sullivan
Journal:  Psychiatr Serv       Date:  2008-08       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.